Autopsy report · NCT00351858

Safety and Efficacy Study of the Trifunctional Antibody Ertumaxomab to Treat Patients With Advanced or Metastatic Breast Cancer

“company focus on other projects”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 2 years 7 months before it stopped.
• 40 participants planned (an estimate, not an actual count).
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Neovii Biotech

Sponsor type

Industry

Conditions

Breast Neoplasms; Breast Cancer

Interventions

ertumaxomab

Participants

40 (planned, not actual)

Sites

1

Countries

Belgium

Trials that died the same way

• Effect of Guided Imagery on Patients With Chronic Pain Related to Spinal Cord Injury
  “Due to other projects priority” (61% match in meaning)
• A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Alzheimer's Disease
  “Company focus shifted” (60% match in meaning)
• A Pilot Study to Explore the Role of Gut Flora in Gout
  “Company shifted focus” (58% match in meaning)
• POMCO2 Clinical Study MicroTrend System pCO2 Sensor
  “Change in focus by the company.” (58% match in meaning)
• Safety and Efficacy Study of NovoRapid™ in Patients With Coexisting Diabetes and Kidney Disease
  “Due to company decision to focus resources on the finalisation of three ongoing studies in the region” (56% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.